Viracta TherapeuticsVIRX
About: Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
Employees: 40
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
5% less funds holding
Funds holding: 40 [Q2] → 38 (-2) [Q3]
9.15% less ownership
Funds ownership: 23.33% [Q2] → 14.17% (-9.15%) [Q3]
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
74% less capital invested
Capital invested by funds: $4.98M [Q2] → $1.29M (-$3.69M) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
RBC Capital Gregory Renza 53% 1-year accuracy 39 / 74 met price target | 1,250%upside $2 | Outperform Maintained | 14 Nov 2024 |
